NY-RAPID-MEDICAL
3.11.2021 13:38:13 CET | Business Wire | Press release
Rapid Medical , a leading developer of advanced neurovascular devices, today announced FDA investigational device exemption (IDE) approval for the first-ever trial to expand interventional stroke treatment to distal regions of the brain. The DISTALS Study is a pivotal, international, multi-center, randomized controlled trial (RCT) to evaluate the safety and effectiveness of distal thrombectomy. This new frontier for ischemic stroke has been created by Rapid Medical’s development of TIGERTRIEVER™ 13 , the smallest thrombectomy device available.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005702/en/
“We're especially pleased to receive unprecedented FDA IDE approval for a study with DISTALs focus," elates Jeffrey Saver , MD, FAHA, Professor of Neurology and Director of the Comprehensive Stroke and Vascular Neurology Program at UCLA in Los Angeles, CA and principal investigator. "With the ever-growing benefits of mechanical thrombectomy, we hope to offer better recoveries to a much broader patient population. Rapid Medical has been at the forefront of enabling that progress."
Currently, less than 10% of ischemic stroke patients receive mechanical thrombectomy, a well-proven treatment that significantly improves patient outcomes. While Rapid Medical's TIGERTRIEVER 13 has already been used to treat nearly 1500 patients in Europe and the Middle East, the DISTALS Study aims to extend these benefits to an additional 25 – 40% of stroke patients. It focuses on far territories in the brain, such as M3 blood vessels, and allows intervention within 24 hours from symptoms onset.
"The DISTALS trial is critical for the field of interventional stroke therapy,” says David Fiorella , MD, PhD and Director of the Cerebrovascular Center at Stony Brook University Medical Center in Stony Brook, NY and co-coordinating investigator. "It potentially allows us to offer thrombectomy to an additional large group of stroke patients who may benefit substantially.”
Ronen Eckhouse , Co-Founder and CEO of Rapid Medical, says the company plans to start the study in Q421 or early Q122. "We announced this news on World Stroke Day to emphasize its significance. Effective treatment of distal stroke represents a leap forward–to diminishing the devastating effects of stroke."
The leading investigators also include René Chapot, MD, Professor and Department Head of Neuroradiology and Radiology at Alfried Krupp Krankenhaus in Essen, Germany, and Rishi Gupta, MD and Director of Neurocritical Care at Wellstar Health System in Marietta, GA.
About Rapid Medical
Rapid Medical develops the premier, responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER ™17 and 21, COMANECI ™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER ™13 and XL are also CE marked. More information is available at www.rapid-medical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005702/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden18.5.2026 14:30:00 CEST | Press release
The state-of-the-art facility enhances support for complex modalities across all phases of drug developmentKey facts Thermo Fisher opensnew bioanalytical and biomarker laboratory in Gothenburg, Sweden Designed to deliver comprehensive, full-service bioanalytical and biomarker solutions Supports pharmaceutical and biotechnology customers across all phases of drug development Helps customers globally accelerate innovation and bring new therapies to patients faster Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company’s global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the laboratory provides rapid, reliable bioanalytical and biomarker servi
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion18.5.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has received approval from the Taiwan Food and Drug Administration (TFDA) for the Edison® System, representing a significant milestone in the company’s global expansion efforts and continued growth across Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518694013/en/ HistoSonics Edison® Histotripsy System Taiwan is widely recognized as one of the most advanced and strategically important medical device markets in the region, known for its rigorous regulatory standards and highly innovative physician community. The TFDA approval process included a detailed review of the company’s clinical and regulatory submission package and concluded with unanimous agreement from committee members. The approval further reinforces the growing clinical and regulatory momentum behind histotripsy, a non-invasive, non-th
FurtherAI Appoints Tom Bradley to Lead UK and EU Expansion18.5.2026 14:00:00 CEST | Press release
FurtherAI, the AI platform purpose-built for insurance, today announced the appointment of Tom Bradley to lead its UK and EU operations. This marks a significant step in FurtherAI's international expansion, as the company moves to establish a local presence in one of the world's most important insurance markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518611218/en/ FurtherAI Appoints Tom Bradley to lead UK & EU expansion FurtherAI is already working with leading partners in the UK, and Tom's appointment will allow the company to deepen those relationships, build a local team, and serve the rapidly growing demand from carriers, MGAs, and brokers across the Lloyd's market and the wider region. A market moving fast on AI The Lloyd's market and the broader UK and European insurance ecosystem are adopting AI at a pace few would have predicted even twelve months ago. From submission gateways to policy audits to claims, o
Bending Spoons Closes Acquisition of Tractive18.5.2026 13:48:00 CEST | Press release
Technology company Bending Spoons today announced that it has closed the acquisition of Tractive, an Austria-based global leader in location tracking and health monitoring for pets. The definitive acquisition agreement was entered into in March 2026. Michael Hurnaus, Tractive’s CEO and co-founder, said of the acquisition: “Building Tractive into a global leader in pet safety over the past thirteen years has been an extraordinary journey. We set out to give pet owners peace of mind, and grew that mission into a product trusted by millions of people across the world. I'm proud of everything the team has achieved, and excited about how far Tractive will reach under Bending Spoons. Their global platform and technological capabilities will help keep Tractive at the cutting edge, combining our strong European innovation culture with the scale needed to reach even more pet parents around the world.” Luca Ferrari, the Bending Spoons CEO and co-founder, today said: “We’re impressed by what the
Visa and Jason Sudeikis Turn the Simplest Goal in Football Into the Biggest Fan Moments at the FIFA World Cup 2026™18.5.2026 13:00:00 CEST | Press release
With “Tap In,” Visa brings fans closer to the FIFA World Cup 2026™—one effortless tap at a time. At the FIFA World Cup 2026™, everything can change in a split second. A quick pass. A simple finish. A tap in goal. This summer, Visa (NYSE: V), the Worldwide Payment Technology Partner of the FIFA World Cup 2026™, is turning those fleeting moments into something much bigger—launching Tap In, a bold new global campaign based on the belief that everything is a tap in with Visa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518011231/en/ Built around one of football’s most recognizable finishes, Tap In takes the simplest touch in the game and turns it into a powerful metaphor for how Visa works: fast, seamless, and effortless in the moments that matter most. At the FIFA World Cup™, that idea moves beyond storytelling, unlocking opportunity in communities and connecting fans directly to the action as it unfolds live. When Player
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom